{"id":193682,"date":"2026-03-18T08:38:13","date_gmt":"2026-03-18T08:38:13","guid":{"rendered":"https:\/\/www.europesays.com\/se\/193682\/"},"modified":"2026-03-18T08:38:13","modified_gmt":"2026-03-18T08:38:13","slug":"oncopeptides-har-behovt-anvanda-garanter-till-en-tredjedel-av-foretradesemissionen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/193682\/","title":{"rendered":"Oncopeptides har beh\u00f6vt anv\u00e4nda garanter till en tredjedel av f\u00f6retr\u00e4desemissionen"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Oncopeptides f\u00f6retr\u00e4desemission tecknades till cirka 62 procent med st\u00f6d av och utan teckningsr\u00e4tter. Mot bakgrund av detta kommer cirka 33 procent av emissionen att tilldelas garanter, vilket inneb\u00e4r att bolaget tillf\u00f6rs cirka 190 miljoner kronor f\u00f6re emissionskostnader, enligt ett pressmeddelande.\n <\/p>\n<p>Utfallet inneb\u00e4r att bolaget n\u00e4stan drar in det \u00f6nskade beloppet p\u00e5 200 miljoner kronor.\n <\/p>\n<p>Genom emissionen tillkommer cirka 122,6 miljoner nya aktier, vilket inneb\u00e4r att det totala antalet aktier i bolaget \u00f6kar till n\u00e4stan 381,2 miljoner aktier.\n <\/p>\n<p>Oncopeptides har tidigare sagt att emissionen syftar till att st\u00e4rka balansr\u00e4kningen, ge ytterligare utrymme f\u00f6r den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti i Europa samt ta bolagets prekliniska projekt avseende indikationen glioblastom fram till klinisk utvecklingsfas, vilket innefattar genomf\u00f6randet av en inledande s\u00e5 kallad &#8221;window-of-opportunity&#8221;-studie i m\u00e4nniska.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Reno Santic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<br \/>\n <br class=\"col-start-2\"\/><br \/>\n <a class=\"twitter-timeline\" data-width=\"1200\" data-height=\"1000\" data-dnt=\"true\" href=\"https:\/\/twitter.com\/Finwire?ref_src=twsrc%5Etfw\" rel=\"nofollow noopener\" target=\"_blank\">Tweets by Finwire<\/a><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n <br class=\"col-start-2\"\/><br \/>\n newsroom@finwire.se<\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Oncopeptides f\u00f6retr\u00e4desemission tecknades till cirka 62 procent med st\u00f6d av och utan teckningsr\u00e4tter. Mot bakgrund av detta&hellip;\n","protected":false},"author":2,"featured_media":164641,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,6576,34,31,33,32,30],"class_list":["post-193682","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-oncopeptides","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116249277563299045","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/193682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=193682"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/193682\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/164641"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=193682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=193682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=193682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}